Patents by Inventor Gregory A. Dekaban

Gregory A. Dekaban has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD11D antibodies and uses thereof
    Patent number: 11873340
    Abstract: Antibodies to human CD11d, compositions comprising such CD11d antibodies, and methods of using such CD11d antibodies for the treatment of central nervous system trauma including spinal cord injury and traumatic brain injury, as well as systemic inflammatory response following central nervous system trauma.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: January 16, 2024
    Assignees: The University of Western Ontario, Eli Lilly and Company
    Inventors: Gregory Dekaban, Arthur Brown, Lynne Weaver, Allan Barrett, Kristine Kikly
  • ANTI-CD11D ANTIBODIES AND USES THEREOF
    Publication number: 20230183355
    Abstract: Antibodies to human CD11d, compositions comprising such CD11d antibodies, and methods of using such CD11d antibodies for the treatment of central nervous system trauma including spinal cord injury and traumatic brain injury, as well as systemic inflammatory response following central nervous system trauma.
    Type: Application
    Filed: February 24, 2017
    Publication date: June 15, 2023
    Inventors: Gregory DEKABAN, Arthur BROWN, Lynne WEAVER, ALLAN Barrett, Kristine KIKLY
  • Metabolomics profiling of central nervous system injury
    Patent number: 11519899
    Abstract: A method of diagnosing central nervous system injuries such as acquired brain injury (ABI) and/or acquired spinal cord injury (ASI), including mild TBI (concussion or blast wave), mild ASI (contusion, stretch or partial cord transection), non-TBI brain injury and/or non-TSI spinal cord injury in a subject (animal or human). The method includes (a) obtaining a biological test sample from the subject, identifying metabolites in the subject's sample using metabolomics thereby obtaining a subject's metabolite matrix and generating a subject's profile using the patient's metabolite matrix; and (b) using multivariate statistical analysis and machine learning to compare the subject's profile with predetermined set of profiles of CNS injuries and a predetermined set of profiles of controls to determine if the subject has a CNS injury.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: December 6, 2022
    Assignee: LONDON HEALTH SCIENCES CENTRE RESEARCH INC.
    Inventors: Douglas Dale Fraser, Robert Bartha, Arthur Brown, Tanya Charyk Stewart, Mark Daley, Gregory A. Dekaban, Timothy Doherty, Lisa Fischer, Jeffrey Holmes, Ravi Menon, J. Kevin Shoemaker, Charles A. Rupar
  • Methods of treating chronic pain using compositions that specifically bind cd11d (alpha-d) integrin
    Publication number: 20070092515
    Abstract: Methods to treat secondary injury resulting from spinal cord injury using polypeptide compositions that specifically bind to CD11d are disclosed.
    Type: Application
    Filed: November 8, 2004
    Publication date: April 26, 2007
    Applicant: Icos Corporation
    Inventors: Lynne Weaver, Gregory Dekaban, Mark Oatway
  • Human T-cell lymphotropic virus type II envelope protein and human monoclonal antibodies specific therefor
    Patent number: 6270959
    Abstract: Isolated and purified envelope protein of HTLV-I is provided devoid of non-envelope protein of HTLV-I and having substantially the same conformation as the envelope protein in native HTLV-I. The protein is produced recombinantly using a dual vaccinia/T7 polymerase system. Non-glycosylated and glycosylated forms of the protein are produced. Glycosylated forms are recognized by antibodies specific for the envelope protein of HTLV-I. Monoclonal antibodies are provided which are specific for the HTLV-I envelope protein and non-binding to HTLV-I envelope protein in denatured form. The HTLV-I envelope protein is cross-reactive with antibodies of HTLV-II and STLV. The envelope protein is useful in diagnosis of infection by HTLV-I and HTLV-II.
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: August 7, 2001
    Inventors: Gregory A. Dekaban, Jacqueline Arp, Steven Kok Hing Foung
  • Human T-cell lymphotropic virus type I envelope protein and human monoclonal antibodies specific therefor
    Patent number: 5961984
    Abstract: Isolated and purified envelope protein of HTLV-I is provided devoid of non-envelope protein of HTLV-I and having substantially the same conformation as the envelope protein in native HTLV-I. The protein is produced recombinantly using a dual vaccinia/T7 polymerase system. Non-glycosylated and glycosylated forms of the protein are produced. Glycosylated forms are recognized by antibodies specific for the envelope protein of HTLV-I. Monoclonal antibodies are provided which are specific for the HTLV-I envelope protein and non-binding to HTLV-I envelope protein in denatured form. The HTLV-I envelope protein is cross-reactive with antibodies of HTLV-II and STLV. The envelope protein is useful in diagnosis of infection by HTLV-I and HTLV-II.
    Type: Grant
    Filed: April 2, 1996
    Date of Patent: October 5, 1999
    Assignees: University of Western Ontario, Stanford University
    Inventors: Gregory A. Dekaban, Jacqueline Arp, Steven Kok Hing Foung